Minerva Neurosciences Inc. appointed Michael Davidson chief medical officer, to lead strategic development and clinical advancement of the company's products for schizophrenia, insomnia, major depressive disorder and Parkinson's disease.

Davidson is professor of psychiatry at the Sackler School of Medicine, Tel Aviv University, and has worked as a consultant for Pfizer Inc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Roche Holding Ltd., Novartis AG, Eli Lilly & Co., BioLineRx Ltd. and Takeda Pharmaceutical Co. Ltd., among others.